This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK (
TheStreet) -- April is the most bountiful month of the year when it comes to the stock market, Jim Cramer told his
"Mad Money" TV show viewers Monday. That's why Cramer is pushing the skeptics aside and reviewing his "Do Something" list of stocks that are taking charge of their own destinies.
Cramer first debuted his "Do Something" list on Nov. 29 and since then the 10 stocks have risen 23.9%, far more than the market's 10.2% rise.
Leading the group is
Hess(HES), which continues to sell assets to unlock its hidden value. Then there is
Deckers Outdoor(DECK), which has risen 45% thanks to a cold winter.
Manitowoc(MTW) remains a company worth breaking up, Cramer contended, as is
Mine Safety Appliance(MSA), which are up 33% and 29%, respectively, since being added to the list.
Fortune Brands Home & Security(FBHS) remains a takeover target, said Cramer, even with that stock up 22%.
Also on the list:
Johnson & Johnson(JNJ), a stock Cramer owns for his charitable trust,
Action Alerts PLUS
, up 18% as it continues to clean up its act. There's also
Alliant Tech(ATK), a defense name with a 16% gain in the face of the sequester.
Bed Bath & Beyond(BBBY), a company ripe for a private equity takeover, and
Hain Celestial(HAIN), the only laggard in the group, trading essentially flat since November.
Cramer said he'd still be a buyer of all these names except, perhaps, Hess, which has lost some luster because it has already unlocked much of its value.
The future of drug stocks isn't with Big Pharma, Cramer told viewers, it's with smaller biotech names. That's why Cramer continued his in-depth look at the biotech sector by taking a peek at some of the smaller, more speculative companies that treat orphan diseases. He reminded viewers that while orphan drugs often treat fewer than 200,000 patients, thanks to Food and Drug Administration protections companies can charge upwards of $200,000 per year per patient for some of these cutting-edge therapies.
Among his favorites in the group are
Alexion Pharmaceuticals(ALXN - Get Report) and
BioMarin Pharmaceuticals(BMRN - Get Report), two stocks up huge over the past year.